Similar to the pan-cancer activity demonstrated by a combination of SI-12 with the DNMT inhibitor SGI1027, combining SI-12 with the RhoA inhibitor CCG1423 also resulted in potent anti-cancer activity in PANC-1 and LNCaP cells in addition to that seen in MCF-7 cells. Here, RHOA is linked to cancer.